Latest On PhaseBio Pharmaceuticals, Inc (PHAS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-10-24 11:18 EST | News | PhaseBio announces Chapter 11 filing; plans to sell lead asset | N/A |  |
| 2022-09-28 23:12 EST | News | PhaseBio sinks ~67% after getting transfer notice for lead drug bentracimab's business | N/A | |
| 2022-08-12 23:41 EST | News | PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M | N/A | |
| 2022-05-16 17:30 EST | News | PhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43 | N/A | |
| 2022-05-16 17:30 EST | News | PhaseBio to seek FDA approval for clotting agent in 4Q 2022 | N/A | |
About PhaseBio Pharmaceuticals, Inc (PHAS):
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio read more... Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
General
- Name PhaseBio Pharmaceuticals, Inc
- Symbol PHAS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 50
- Fiscal Year EndDecember
- IPO Date2018-10-18
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://phasebio.com
Valuation
- Price/Sales (Trailing 12 Mt.) 103.44
- Price/Book (Most Recent Quarter) 26.18
- Enterprise Value Revenue 83.17
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.75
- Next Year EPS Estimate -$2.45
- Next Quarter EPS Estimate -$0.72
- Operating Margin -26518%
- Return on Assets -80%
- Return on Equity -567%
- Revenue 320000
- Earnings Per Share -$1.62
- Revenue Per Share $0.01
- Gross Profit -71768000
- Quarterly Earnings Growth -100%
Highlights
- Market Capitalization 126.9 million
- EBITDA -29400000
- Analyst Target Price $13.75
- Book Value Per Share $0.15
Share Statistics
- Shares Outstanding 29.44 million
- Shares Float 15.54 million
- % Held by Insiders 1118%
- % Held by Institutions 68.74%
- Shares Short 3.14 million
- Shares Short Prior Month 3.13 million
- Short Ratio 8.57
- Short % of Float 24%
- Short % of Shares Outstanding 11%
Technicals
- Beta 1.81
- 52 Week High $6.35
- 52 Week Low $2.6
- 50 Day Moving Average 4.21
- 200 Day Moving Average 3.77
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
PhaseBio Pharmaceuticals, Inc (PHAS) Dividend Calendar:
PhaseBio Pharmaceuticals, Inc (PHAS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
PhaseBio Pharmaceuticals, Inc (PHAS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
PhaseBio Pharmaceuticals, Inc (PHAS) Chart:
PhaseBio Pharmaceuticals, Inc (PHAS) News:
Below you will find a list of latest news for PhaseBio Pharmaceuticals, Inc (PHAS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
PhaseBio Pharmaceuticals, Inc (PHAS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest PHAS Trades:
PhaseBio Pharmaceuticals, Inc (PHAS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-23 | 8-K (Current report) | |
| 2020-10-06 | 8-K (Current report) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-11 | 8-K (Current report) | |
| 2020-08-11 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-16 | 8-K (Current report) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 8-K (Current report) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-27 | 8-K (Current report) | |
| 2020-05-12 | 8-K (Current report) | |
| 2020-05-12 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
PhaseBio Pharmaceuticals, Inc (PHAS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of PhaseBio Pharmaceuticals, Inc (PHAS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1118%
Institutional Ownership: 6874%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-01 | Susan Elizabeth Arnold | VP, Preclinical and Chem | Buy | 5,423.00 | 1.15 | 6,236.45 | 13,152.00 | |
| 2020-08-21 | Jonathan P Mow | Chief Executive Officer | Buy | 10,000.00 | 1.24 | 12,400.00 | 119,243.00 | |
| 2020-08-14 | John P Sharp | Chief Financial Officer | Buy | 5,000.00 | 1.69 | 8,450.00 | 40,000.00 | |
| 2019-09-06 | Jonathan P Mow | Chief Executive Officer | Buy | 19,000.00 | 1.24 | 23,560.00 | 109,243.00 | |
| 2019-08-21 | John P Sharp | CFO and Secretary | Buy | 10,000.00 | 1.69 | 16,900.00 | 30,000.00 | |
| 2019-08-21 | John P Sharp | CFO and Secretary | Buy | 5,000.00 | 1.44 | 7,200.00 | 35,000.00 | |
| 2019-07-01 | Clay Thorp | Director | Sell | 180.00 | 14.00 | 2,520.00 | 162,890.00 | |
| 2019-07-01 | Clay Thorp | Director | Sell | 2,014.00 | 14.00 | 28,196.00 | 1,818,638.00 | |
| 2019-07-01 | Clay Thorp | Director | Sell | 459.00 | 14.00 | 6,426.00 | 415,959.00 | |
| 2019-07-01 | Clay Thorp | Director | Sell | 255.00 | 14.00 | 3,570.00 | 52,397.00 | |
| 2019-06-18 | Clay Thorp | Director | Sell | 25.00 | 14.00 | 350.00 | 163,074.00 | |
| 2019-06-18 | Clay Thorp | Director | Sell | 277.00 | 14.00 | 3,878.00 | 1,820,656.00 | |
| 2019-06-18 | Clay Thorp | Director | Sell | 63.00 | 14.00 | 882.00 | 416,418.00 | |
| 2019-06-18 | Clay Thorp | Director | Sell | 35.00 | 14.00 | 490.00 | 52,655.00 | |
| 2019-05-22 | John P Sharp | CFO and Secretary | Buy | 15,000.00 | 1.69 | 25,350.00 | 20,000.00 | |
| 2019-05-20 | Jonathan P Mow | Chief Executive Officer | Buy | 19,131.00 | 1.24 | 23,722.44 | 90,243.00 | |
| 2019-05-17 | Jonathan P Mow | Chief Executive Officer | Buy | 19,913.00 | 2.27 | 45,202.51 | 71,112.00 | |
| 2018-12-17 | Nancy J Hutson | Director | Buy | 1,000.00 | 4.46 | 4,460.00 | 1,000.00 | |
| 2018-12-13 | Jonathan P Mow | Chief Executive Officer | Buy | 1,000.00 | 3.69 | 3,690.00 | 51,199.00 | |
| 2018-12-13 | David James Ballance | VP, Research and Sci. Affairs | Buy | 1,000.00 | 3.94 | 3,940.00 | 7,600.00 | |